Literature DB >> 10752992

Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome.

H J Deeg1, C Beckham, M R Loken, E Bryant, M Lesnikova, H M Shulman, T Gooley.   

Abstract

The mechanism that leads to hemopoietic failure in patients with myelodysplastic syndrome (MDS) is not well understood. There is evidence, however, that regulatory molecules such as tumor necrosis factor (TNF)-alpha, Fas (CD95), and Fas-ligand, which negatively affect hemopoiesis by way of apoptosis are upregulated. Here we analyzed marrow samples from 80 patients with MDS in regard to TNF-alpha and Fas-ligand levels and a possible correlation with various disease parameters and risk factors. TNF-alpha levels were elevated in comparison to samples from normal marrow donors, however, no significant correlation with FAB subtype, cytogenetic risk group or score by the International Prognostic Scoring System (IPSS) was observed. However, there was an inverse correlation between the cytogenetic risk category (low, intermediate, high) and levels of soluble Fas-ligand. The major source of TNF-alpha were mononuclear (non-stromal) cells which appeared to produce TNF-alpha at maximum levels. Limiting dilution analysis of CD34+ precursor cells showed that individually assayed cells, removed from companion cells that presumably provided negative signals such as TNF-alpha or Fas-ligand, were able to generate progressively increasing numbers of colonies. Stromal layers derived from MDS marrow did not have an inhibitory effect. In fact, higher colony numbers were obtained from both normal and MDS marrow derived hemopoietic precursors propagated on irradiated stromal layers from MDS marrow than on stromal layers from normal marrow. These results show that substantial numbers of normal hemopoietic precursors persist in MDS marrow. However, differentiation into mature cells is inhibited by negative signals originating from accessory or abnormal hemopoietic precursors in the non-adherent marrow fraction.

Entities:  

Mesh:

Year:  2000        PMID: 10752992     DOI: 10.3109/10428190009089441

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  35 in total

Review 1.  Molecular biology of myelodysplastic syndromes.

Authors:  Alan H Shih; Ross L Levine
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

2.  Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.

Authors:  Bart L Scott; Aravind Ramakrishnan; Mark Fosdal; Barry Storer; Pamela Becker; Steve Petersdorf; H Joachim Deeg
Journal:  Br J Haematol       Date:  2010-03-16       Impact factor: 6.998

3.  Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Authors:  Ruben A Ferrer; Manja Wobus; Catrin List; Rebekka Wehner; Claudia Schönefeldt; Barbara Brocard; Brigitte Mohr; Martina Rauner; Marc Schmitz; Maik Stiehler; Gerhard Ehninger; Lorenz C Hofbauer; Martin Bornhäuser; Uwe Platzbecker
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 4.  Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes.

Authors:  Jingya Wang; Zhijian Xiao
Journal:  Stem Cell Investig       Date:  2014-08-21

Review 5.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

6.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

7.  Apoptotic rate in patients with myelodisplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines.

Authors:  Elena Moldoveanu; Andreea Moicean; Cristina Vidulescu; Daciana Marta; Adriana Colita
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

Review 8.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

9.  Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function.

Authors:  A Mario Marcondes; Andrew J Mhyre; Derek L Stirewalt; Soo-Hyun Kim; Charles A Dinarello; H Joachim Deeg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

10.  Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.

Authors:  Merav Bar; Derek Stirewalt; Era Pogosova-Agadjanyan; Vitas Wagner; Ted Gooley; Nissa Abbasi; Ravi Bhatia; H Joachim Deeg; Jerald Radich
Journal:  Transl Oncogenomics       Date:  2008-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.